- Motley Fool•2 hours ago
AstraZeneca, Bristol-Myers Squibb, and Pfizer receive good news from the real world.
- Zacks•6 hours ago
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
- Barrons.com•7 hours ago
Credit Suisse One of the most common topics of discussion in our investor meetings remains the question around whether Pfizer or another biopharma company may be interested in acquiring Bristol-Myers Squibb in the next nine-12 months, given some of the challenges Bristol-Myers is facing and the activist involvement in the name. To supplement our previous work, our HOLT [proprietary Credit Suisse platform] colleagues have now taken a look at the possibility of Pfizer buying Bristol-Myers from a HOLT perspective and do see the deal as providing an opportunity for value-creation.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||33.97 - 34.26|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.12|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|